Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIOC11
- Development stage
- Preclinical
- Lead developer
- Vast Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
BIOC11 is a preclinical **nitric oxide-releasing anti-infective drug candidate** being developed by Vast Therapeutics, a subsidiary of KNOW Bio, for chronic pulmonary infections associated with cystic fibrosis. The agent uses a proprietary **water-soluble nitric oxide-releasing biopolymer** technology in a **synthetically derived powder-based formulation** to deliver nitric oxide locally as a small-molecule antimicrobial payload. Its proposed mechanism is direct killing of bacterial pathogens through nitrosative and oxidative damage to microbial cellular components, including DNA, with reported activity against *Pseudomonas aeruginosa*, other antibiotic-resistant bacteria, and nontuberculous mycobacteria in animal models. BIOC11 received FDA Qualified Infectious Disease Product designation in 2019, supporting potential priority review and fast-track eligibility if clinical development advances.
- Other names
- nitric oxide-releasing biopolymernitric oxide
Beyond the preview
Go deeper on BIOC11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIOC11.